NEW YORK, April 10 - Sequenom and Provid Pharmaceuticals today said they plan to co-develop small-molecule therapeutics based on cardiovascular targets discovered by Sequenom.
 
Terms of the deal call for privately held Provid to receive an equity investment and research funding, and to be eligible for milestones and royalties on any products that may arise.

Financial details of the collaboration were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.